Perbandingan Rerata Kadar ICAM-1 pada Pasien Stroke Iskemik Akut yang Mendapatkan Terapi Simvastatin dan Tidak

Ahmad Thobroni Ali Mukhtar*, Abdulloh Machin**

* Peserta PPDS I Neurologi FK Universitas Airlangga/RSUD Dr. Soetomo Surabaya
** Staf Pengajar SMF/Departemen Neurologi FK Universitas Airlangga/RSUD Dr. Soetomo Surabaya

Abstract

         Latar belakang dan Tujuan: Stroke telah menjadi penyebab kematian utama di hampir semua rumah sakit di Indonesia. Terapi statin telah merubah manajemen penyakit pembuluh darah dalam hal pencegahan primer dan sekunder stroke. Tujuan penelitian untuk mengetahui perbedaan rerata kadar ICAM-1 pada pasien stroke iskemik akut mendapat terapi simvastatin dan yang tidak mendapat terapi simvastatin selama masa rawat fase akut di rumah sakit. Metode: Rancangan penelitian adalah randomized controlled trial study. Sampel diambil dari semua penderita stroke iskemik akut yang menjalani perawatan di Bagian Neurologi FK Unair/ SMF Neurologi RSUD Dr. Soetomo Surabaya dan Rumah Sakit Universitas Airlangga Surabaya yang memenuhi kriteria inklusi dan menggunakan teknik pengambilan sampel pada ISIM study. Analisa data menggunakan Wilcoxon signed ranks test dan One-Way ANOVA. Hasil: Kadar rata-rata serum ICAM-1 pada kelompok perlakuan tidak menunjukkan peningkatan yang signifikan masing-masing kadar ICAM-1 antara sebelum pemberian simvastatin 20 mg yaitu 165,58 (25,88 – 2685,44) ng/ml dan setelah pemberian simvastatin 20 mg hari kelima 255,59 (30,32 – 1159,11) ng/ml dengan signifikansi P = 0,274. Kesimpulan: Tidak didapatkan pengaruh pada pemberian simvastatin 20 mg terhadap penurunan kadar serum ICAM-1 pada pasien stroke iskemik akut dibandingkan dengan kelompok kontrol.

Kata Kunci:
ICAM-1, NIHSS, Simvastatin, Stroke iskemik akut

Daftar Pustaka

  1. Thorvaldsen P, Kuulasmaa K, Rajakangas A-M, et al. Stroke trends in the WHO. MONICA project. Stroke 1997; 28: 500 LP-506.
  2. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American heart association/American stroke association. Stroke 2013; 44: 2064–2089.
  3. Badan Penelitian dan Pengembangan Kesehatan Kesehatan RI. Badan Penelitian dan Pengembangan Kesehatan Kementrian kesehatan RI. 2013.
  4. Bonaventura A, Liberale L, Vecchié A, et al. Update on inflammatory biomarkers and treatments in ischemic stroke. Int J Mol Sci. 2016; 17: 1–53.
  5. Mir MA, Albaradie RS. Inflammatory mechanisms as potential therapeutic targets in stroke. Adv Neuroimmune Biol. 2014; 5: 199–216.
  6. Niessen HW, Krijnen PA., Visser CA, et al. Intercellular adhesion molecule-1 in heart. 66.
  7. Jordán J, Segura T, Brea D, et al. Inflammation as therapeutic objective in stroke. Curr Pharm. 2008;14: 3549–64.
  8. Zhao J, Zhang X, Dong L, et al. The many roles of statins in ischemic stroke. Curr Neuropharmacol. 2014; 12: 564–574.
  9. Basniwal PK, Jain D. Simvastatin: Review of updates on recent trends in pharmacokinetics, pharmacodynamics, drugdrug interaction, impurities and analytical methods. Curr Pharm Anal. 2012; 8: 135–156.
  10. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109: III-39-III-43.
  11. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol. 2009; 8: 345–354.
  12. Ameliorates S, Cerebrovascular R, Channel C. During Hypertension via Inhibition of Volume-Regulated Chloride Channel. Epub ahead of print 2010. B. DOI: 10.1161/HYPERTENSIONAHA.110.150102.
  13. Fiscella K, Franks P, Liu L, et al. Diabetes, the metabolic syndrome, and ischemic stroke epidemiology and possible mechanisms. Med Sci Sports Exerc. 2014; 302: 11-18.
  14. Lennihan L, Kupsky WJ, Mohr JP, et al. Lack of Association Between Carotid Plaque Hematoma and Ischemic Cerebral Symptoms. 1987; 879–882.
  15. Banerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: the northern manhattan study. Stroke. 2012; 43: 1212–1217.
  16. Gratziou C. Respiratory diseases : a high priority, integral. 2007; 29: 390–417.
  17. Adibhatla, R., & Hatcher, J. Cytidine 5’-diphosphocholine (CDPCholine) in stroke and other CNS disorders. Neurochem. 2005. 15-23.
  18. Deb, P., & Sharma, S. Pathophysiologic mechanism of acute ischemic stroke : an overiew with emphasis on therapeutic significance beyond thrombolysis pathophysiology. 2010; 17: 197-218.
  19. Blum a, Khazim K, Merei M, et al. The stroke trial – can we predict clinical outcome of patients with ischemic stroke by measuring soluble cell adhesion molecules (CAM)?. Eur Cytokine Netw. 2006; 17: 295–298.